Design and analysis choices for safety surveillance evaluations need to be tuned to the specifics of the hypothesized drug-outcome association. (Pubmed Abstract) Authors Gruber S, Chakravarty A, Heckbert SR, Levenson M, Martin D, Nelson JC, Psaty BM, Pinheiro S, Reich CG, Toh S, Walker AM Abbreviation Pharmacoepidemiol Drug Saf Volume 25 Issue 9 Publication Date 2016-07-14